mol42
01 Aug 2018
200k share buy today 010818 not surprised at this price! 11:51:34 01-Aug-2018 25.11 GBX 200,000 50,228.00 Off-book AIMX LRGS but welcome nevertheless not me btw - lol mol
mol42
31 Jul 2018
R Lowi 310718 [link] mol
Ripley94
30 Jul 2018
covance 050218 AVCT… RNS placing today @ 25p share price dropped 27% top of fall list AIM
mol42
30 Jul 2018
Fund raising oops meant to add no doubt AS will give interview soon - probably after confirmation though hope he’s asked how this was handled … and pushed on how badly not - lol mol
mol42
30 Jul 2018
Fund raising confirmed subject to shareholders meeting to approve enlarged sc [link] and on same day hardman note! [link] thought AS didn’t look himself in recent interview - now we know why badly handled by all concerned but especially BOD - bw to all who bought in on previous rns and further director investment extremely poor - apart from perhaps new non-exec chairman - perhaps extremely disappointed on how this was handled - did expect more fund raising - but never like this anyway good entry point at 25p for those who were invited! bw all mol
mol42
25 Jul 2018
A Smith Interview 250718 [link] wrt latest rns mol
Ripley94
24 Jul 2018
covance 050218 AVCT… XXXXX Top riser today up 52% to 43.5 p but still below my last top up in March 2018. Maybe a better time to buy after a big rise like this.
mol42
14 Jun 2018
A Smith Interview This afternoon Proactiveinvestors UK Avacta Group Plc focused on securing third-party deals for both sides of the... Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), talks Proactive's Andrew Scott through the latest developments across the business. mol
Proverbs 26 vs 5
12 May 2018
Re: Turner Pope/ Capital Network 160418 "The entire process of developing a drug from preclinical research to marketing can take approximately 12 to 18 years and often costs well over $1 billion." That is assuming that the trials are a "clinical success".========== ========== ========== ========== ========== ========== ========== ==It all seemed so promising for Prothema before the Phase III trial..."We have just heard from Prothena that the Pronto trial, investigating NEOD001 in AL Amyloidosis, has not met its primary endpoint. This is an extremely disappointing outcome and one which has surprised the company, with a much bigger and more significant placebo effect being observed than anything seen in prior trials would have suggested. As a result, Prothena has announced that it will halt all spending on NEOD001 immediately, including the termination of the ongoing Vital study, which had been due to read-out next year."[link]
mol42
11 May 2018
Re: Turner Pope/ Capital Network 160418 up to 20 now! jees loltopped up todaybw allmol
mol42
06 May 2018
Re: Turner Pope/ Capital Network 160418 riccardo capital network now on youtube re interims[link] mighty 4 views - and one minemol
mol42
29 Apr 2018
Trades 270418 16:24:41 27-Apr-18 31.00 GBX 60,000 18,600.00 Off-book AIMX LRGS16
9:25 27-Apr-18 31.00 GBX 123,500 38,285.00 Off-book AIMX LRGS10:37:55 27-Apr-18 30.02 GBX 1,000 300.20 Off-book AIMX 08:55:19 27-Apr-18 30.30 GBX 241 73.02 Off-book AIMX 08:39:35 27-Apr-18 30.30 GBX 5,000 1,515.00 Off-book AIMX from london stock exchangewho reports high 31.50 low 30.50nevermind cannot find said high trade though last two welcomemol
mol42
20 Apr 2018
Re: Turner Pope/ Capital Network 160418 i havegood luck with your 6 figure sum[link]
Proverbs 26 vs 5
19 Apr 2018
Re: Turner Pope/ Capital Network 160418 I note with interest that the company is targeting phase 1 trials of their PD-L1 affimers on 2020/2021. The following wikipedia article outlines what this involves:[link] the last sentence of the article"The entire process of developing a drug from preclinical research to marketing can take approximately 12 to 18 years and often costs well over $1 billion." That is assuming that the trials are a "clinical success".I also note the fo;;owing paragraph:Cash outflow from operations was £3.6m in H1 2018 compared to an outflow of £3.0m in H1 2017. At the end of January 2018, the company reported cash of £8.275m compared to cash and short term deposits totalling £13.2m at the end of July 2017 and £16.1m at the end of January 2017. During the interim period, Avacta transferred £4.0m of funds from short term deposits in order to fund ongoinggroup operations.Net assets as of 31 January 2018 were £26.2m, down from £29.9m at the end of July 2017 predominantly as a function of the reduced cash balances.DYORI have over a six figure sum invested in the healthcare market sector but I don't see myself moving any of in into Avacta unless it looks like they were about to be eaten by one of the big beasts. Then a takeover premium would be interesting.
mol42
18 Apr 2018
Turner Pope/ Capital Network 160418 in addition to Hardman note [link] haven't but under daily reviewbw allmol
